These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 27650868)

  • 1. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.
    Zieglmayer P; Focke-Tejkl M; Schmutz R; Lemell P; Zieglmayer R; Weber M; Kiss R; Blatt K; Valent P; Stolz F; Huber H; Neubauer A; Knoll A; Horak F; Henning R; Valenta R
    EBioMedicine; 2016 Sep; 11():43-57. PubMed ID: 27650868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.
    Niederberger V; Neubauer A; Gevaert P; Zidarn M; Worm M; Aberer W; Malling HJ; Pfaar O; Klimek L; Pfützner W; Ring J; Darsow U; Novak N; Gerth van Wijk R; Eckl-Dorna J; Focke-Tejkl M; Weber M; Müller HH; Klinger J; Stolz F; Breit N; Henning R; Valenta R
    J Allergy Clin Immunol; 2018 Aug; 142(2):497-509.e9. PubMed ID: 29361332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG
    Eckl-Dorna J; Weber M; Stanek V; Linhart B; Ristl R; Waltl EE; Villazala-Merino S; Hummel A; Focke-Tejkl M; Froeschel R; Neubauer A; Henning R; Perkmann T; Valenta R; Niederberger V
    EBioMedicine; 2019 Dec; 50():421-432. PubMed ID: 31786130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.
    Focke-Tejkl M; Weber M; Niespodziana K; Neubauer A; Huber H; Henning R; Stegfellner G; Maderegger B; Hauer M; Stolz F; Niederberger V; Marth K; Eckl-Dorna J; Weiss R; Thalhamer J; Blatt K; Valent P; Valenta R
    J Allergy Clin Immunol; 2015 May; 135(5):1207-7.e1-11. PubMed ID: 25441634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification, epitope mapping and genotype cross-reactivity of hepatitis B preS-specific antibodies in subjects vaccinated with different dosage regimens of BM32.
    Tulaeva I; Cornelius C; Zieglmayer P; Zieglmayer R; Schmutz R; Lemell P; Weber M; Focke-Tejkl M; Karaulov A; Henning R; Valenta R
    EBioMedicine; 2020 Sep; 59():102953. PubMed ID: 32855110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype.
    Marth K; Breyer I; Focke-Tejkl M; Blatt K; Shamji MH; Layhadi J; Gieras A; Swoboda I; Zafred D; Keller W; Valent P; Durham SR; Valenta R
    J Immunol; 2013 Apr; 190(7):3068-78. PubMed ID: 23440415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection.
    Cornelius C; Schöneweis K; Georgi F; Weber M; Niederberger V; Zieglmayer P; Niespodziana K; Trauner M; Hofer H; Urban S; Valenta R
    EBioMedicine; 2016 Sep; 11():58-67. PubMed ID: 27568223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A B Cell Epitope Peptide Derived from the Major Grass Pollen Allergen Phl p 1 Boosts Allergen-Specific Secondary Antibody Responses without Allergen-Specific T Cell Help.
    Narayanan M; Freidl R; Focke-Tejkl M; Baranyi U; Wekerle T; Valenta R; Linhart B
    J Immunol; 2017 Feb; 198(4):1685-1695. PubMed ID: 28093528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope-based grass pollen allergy vaccine with allergen extract-based vaccines.
    Weber M; Niespodziana K; Linhart B; Neubauer A; Huber H; Henning R; Valenta R; Focke-Tejkl M
    J Allergy Clin Immunol; 2017 Nov; 140(5):1433-1436.e6. PubMed ID: 28576673
    [No Abstract]   [Full Text] [Related]  

  • 10. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects.
    Winther L; Malling HJ; Mosbech H
    Allergy; 2000 Sep; 55(9):827-35. PubMed ID: 11003446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-response relationship of a new Timothy grass pollen allergoid in comparison with a 6-grass pollen allergoid.
    Pfaar O; Hohlfeld JM; Al-Kadah B; Hauswald B; Homey B; Hunzelmann N; Schliemann S; Velling P; Worm M; Klimek L
    Clin Exp Allergy; 2017 Nov; 47(11):1445-1455. PubMed ID: 28696503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allergome-wide peptide microarrays enable epitope deconvolution in allergen-specific immunotherapy.
    Mikus M; Zandian A; Sjöberg R; Hamsten C; Forsström B; Andersson M; Greiff L; Uhlén M; Levin M; Nilsson P; van Hage M; Ohlin M
    J Allergy Clin Immunol; 2021 Mar; 147(3):1077-1086. PubMed ID: 32791163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy.
    Aasbjerg K; Backer V; Lund G; Holm J; Nielsen NC; Holse M; Wagtmann VR; Würtzen PA
    Clin Exp Allergy; 2014 Mar; 44(3):417-28. PubMed ID: 24734285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
    Chaker AM; Shamji MH; Dumitru FA; Calderon MA; Scadding GW; Makatsori M; Jones I; He QA; Subramanian KK; Arm JP; Durham SR; Schmidt-Weber CB
    J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.
    Gadermaier E; Staikuniene J; Scheiblhofer S; Thalhamer J; Kundi M; Westritschnig K; Swoboda I; Flicker S; Valenta R
    Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
    Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
    J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: clinical and immunological effects.
    Ceuppens JL; Bullens D; Kleinjans H; van der Werf J;
    Clin Exp Allergy; 2009 Dec; 39(12):1903-9. PubMed ID: 20085600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of antibody responses among clinical responders during grass pollen sublingual immunotherapy.
    Baron-Bodo V; Horiot S; Lautrette A; Chabre H; Drucbert AS; Danzé PM; Sénéchal H; Peltre G; Galvain S; Zeldin RK; Horak F; Moingeon P
    Clin Exp Allergy; 2013 Dec; 43(12):1362-73. PubMed ID: 24261946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.
    Klimek L; Schendzielorz P; Pinol R; Pfaar O
    Clin Exp Allergy; 2012 Jun; 42(6):936-45. PubMed ID: 22909165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.